Future perspectives in modulator therapies for Cystic Fibrosis: Advances and challenges

Authors

DOI:

https://doi.org/10.33448/rsd-v13i5.45653

Keywords:

Cystic fibrosis; Modulator therapies; CFTR gene; Treatment.

Abstract

Cystic fibrosis (CF) is a complex and progressive autosomal recessive genetic disease caused by mutations in the CFTR gene, affecting multiple systems of the human body, mainly the pulmonary and digestive systems. This article aims to review current therapies and challenges faced in CF treatment, focusing on CFTR modulator therapies. A review of the available scientific literature on the subject was conducted, including articles from specialized journals, clinical studies, and systematic reviews from the past 10 years. Studies addressing current therapies, mechanisms of action of CFTR modulator therapies, treatment challenges, and future perspectives were selected. The data were analyzed and synthesized to provide a comprehensive view of the current state and future directions in the field of cystic fibrosis treatment.

References

Alibakhshi, R., Mohammadi, A., Khamooshian, S., Kazeminia, M., & Moradi, K. (2021). CFTR gene mutation spectrum among 735 Iranian patients with cystic fibrosis: A comprehensive systematic review. Pediatric Pulmonology, 56(12), 3644-3656. https://doi.org/10.1002/ppul.25647

Aslam, A. A., Sinha, I. P., & Southern, K. W. (2023). Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews, 3(3), CD012040. https://doi.org/10.1002/14651858.CD012040.pub3

Fidler, M. C., Buckley, A., Sullivan, J. C., Statia, M., Boj, S. F., Vries, R. G. J., Munck, A., Higgins, M., Zita, M. M., Negulescu, P., van Goor, F., & De Boeck, K. (2021). G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect. Clinical and Translational Science, 14(2), 656-663. https://doi.org/10.1111/cts.12927

Furtado, J. de S., Brasiel, P. G. de A., & Luquetti, S. C. P. D. (2023). Profile of the intestinal microbiota of patients with cystic fibrosis: A systematic review. Clinical Nutrition ESPEN, 55, 400-406. https://doi.org/10.1016/j.clnesp.2023.04.008

Griese, M., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Taylor-Cousar, J. L., Withers, N. J., Moskowitz, S. M., & Daines, C. L. (2021). Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 203(3), 381-385. https://doi.org/10.1164/rccm.202008-3176LE

Habib AR, Kajbafzadeh M, Desai S, et al. (2019). Physiotherapy in Cystic Fibrosis: Optimising Techniques to Improve Outcomes. International Journal of Respiratory and Pulmonary Medicine, 6(2), 066.

Heneghan, M., Southern, K. W., Murphy, J., Sinha, I. P., & Nevitt, S. J. (2023). Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database of Systematic Reviews, 11(11), CD010966. https://doi.org/10.1002/14651858.CD010966.pub4

Hodos, R. A., Strub, M. D., Ramachandran, S., Li, L., McCray Jr, P. B., & Dudley, J. T. (2020). Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue. Scientific Reports, 10(1), 20553. https://doi.org/10.1038/s41598-020-76347-0

Jiang, M., Li, Z., Fu, S., Xu, Y., Tan, Y., Jia, W., Jiang, Z., Mo, N., Wei, X., Zhang, R., Zhang, Z., Jiang, G., & Yang, X. (2020). IVS8-5T allele of CFTR is the risk factor in chronic pancreatitis, especially in idiopathic chronic pancreatitis. The American Journal of the Medical Sciences, 360(1), 55-63. https://doi.org/10.1016/j.amjms.2020.04.019

Koumpagioti, D., Moriki, D., Boutopoulou, B., Matziou, V., Loukou, I., Priftis, K. N., & Douros, K. (2023). The Association between CFTR Gene Mutation Heterozygosity and Asthma Development: A Systematic Review. Journal of Clinical Medicine, 12(6), 2403. https://doi.org/10.3390/jcm12062403

Levkova, M., Chervenkov, T., Hachmeriyan, M., & Angelova, L. (2022). CFTR gene variants as a reason for impaired spermatogenesis: a pilot study and a Meta-analysis of published data. Human Fertility, 25(4), 728-737. https://doi.org/10.1080/14647273.2021.1900608

Middleton, P. G., Mall, M. A., Dřevínek, P., et al. (2019). Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. The New England Journal of Medicine, 381(19), 1809-1819. doi:10.1056/NEJMoa1908639

Munck A, Kerem E, Ellemunter H, et al. (2020). Tezacaftor/Ivacaftor in People with Cystic Fibrosis Heterozygous for Minimal Function CFTR Mutations. European Respiratory Journal, 55(6), 1902344. doi:10.1183/13993003.02344-2019

Ooi, C. Y., Syed, S. A., Rossi, L., et al. (2018). CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Frontiers in Pharmacology, 9, 1211. doi:10.3389/fphar.2018.01211

Rowe, S. M., Miller, S., Sorscher, E. J. (2017). Cystic Fibrosis. The New England Journal of Medicine, 377(18), 1762-1769. doi:10.1056/NEJMra1704727

Salazar-Barragan J, Cortes-Hernandez P, Lázaro-Alcántara H, et al. (2023). Glucose Levels in Patients with Cystic Fibrosis Treated with Elexacaftor, Tezacaftor, and Ivacaftor: A Systematic Review and Meta-Analysis. Journal of Cystic Fibrosis, 22(1), 1-9. doi:10.1016/j.jcf.2022.05.013

Shi, R., Wang, X., Lu, X., Zhu, Z., Xu, Q., Wang, H., Song, L., & Zhu, C. (2020). A systematic review of the clinical and genetic characteristics of Chinese patients with cystic fibrosis. Pediatric Pulmonology, 55(11), 3005-3011. https://doi.org/10.1002/ppul.24980

Silva Filho LVRF, Athanazio RA, Tonon CR, et al. (2024). Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis. Jornal Brasileiro de Pneumologia, 49(6), e20230187. doi:10.36416/1806-3756/e20230187

Southern, K. W., Murphy, J., Sinha, I. P., & Nevitt, S. J. (2020). Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database of Systematic Reviews, 12(12), CD010966. https://doi.org/10.1002/14651858.CD010966.pub3

Vijftigschild LA, Berkers G, Dekkers JF, et al. (2016). CFTR Correctors Rescue the Mutant CFTR Channel by Restoring Its Protein Trafficking and Function. American Journal of Physiology. Lung Cellular and Molecular Physiology, 311(6), L1110-L1123. doi:10.1152/ajplung.00198.2016

Zemanick, E. T., Taylor-Cousar, J. L., Davies, J., Gibson, R. L., Mall, M. A., McKone, E. F., McNally, P., Ramsey, B. W., Rayment, J. H., Rowe, S. M., Tullis, E., Ahluwalia, N., Chu, C., Ho, T., Moskowitz, S. M., Noel, S., Tian, S., Waltz, D., Weinstock, T. G., Xuan, F., Wainwright, C. E., & McColley, S. A. (2021).

Downloads

Published

04/05/2024

How to Cite

SANTOS, L. H. C. dos .; COUTO, V. C. S. .; SOBRAL, L. O. F. .; SAMPAIO, J. C. R. .; CAVALCANTI, M. G. R. F. .; RUFINO, A. F.; PIRES, L. di P. S. .; MORAES, T. A. de .; GÓES, B. O.; SOARES , E. A. O. C. . Future perspectives in modulator therapies for Cystic Fibrosis: Advances and challenges. Research, Society and Development, [S. l.], v. 13, n. 5, p. e0613545653, 2024. DOI: 10.33448/rsd-v13i5.45653. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/45653. Acesso em: 29 jun. 2024.

Issue

Vol. 13 No. 5

Section

Health Sciences

License

Copyright (c) 2024 Luiz Henrique Cunha dos Santos; Victoria Carolyna Silva Couto; Letícia Ohana Ferreira Sobral; Julia Cartaxo Ramos Sampaio; Maria Gerliane Rodrigues Fonseca Cavalcanti; Antunnes Fama Rufino; Larissa di Paula Souza Pires; Thalia Almeida de Moraes; Bruno Oliveira Góes; Eduardo Antunes Oliveira Cavalcanti Soares

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.